FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023685040> ?p ?o ?g. }

• W2023685040 endingPage "2602" @default.
• W2023685040 startingPage "2594" @default.
• W2023685040 abstract "The authors conducted exploratory phase 1-2 clinical trials vaccinating breast cancer patients with E75, a human leukocyte antigen (HLA) A2/A3-restricted HER-2/neu (HER2) peptide, and granulocyte-macrophage colony-stimulating factor. The vaccine is given as adjuvant therapy to prevent disease recurrence. They previously reported that the vaccine is safe and effective in stimulating expansion of E75-specific cytotoxic T cells. Here, they report 24-month landmark analyses of disease-free survival (DFS).These dose escalation/schedule optimization trials enrolled lymph node-positive and high-risk lymph node-negative patients with HER2 (immunohistochemistry [IHC] 1-3(+) ) expressing tumors. HLA-A2/A3(+) patients were vaccinated; others were followed prospectively as controls for recurrence. DFS was analyzed by Kaplan-Meier curves; groups were compared using log-rank tests.Of 195 enrolled patients, 182 were evaluable: 106 (58.2%) in the vaccinated group and 76 (41.8%) in the control group. The 24-month landmark analysis DFS was 94.3% in the vaccinated group and 86.8% in the control group (P = .08). Importantly, because of trial design, 65% of patients received a lower than optimal vaccine dose. In subset analyses, patients who benefited most from vaccination (vaccinated group vs control group) had lymph node-positive (DFS, 90.2% vs 79.1%; P = .13), HER2 IHC 1+-2+ (DFS, 94.0% vs 79.4%; P = .04), or grade 1 or 2 (DFS, 98.4% vs 86.0%; P = .01) tumors and were optimally dosed (DFS, 97.3% vs 86.8%; P = .08). A booster program has been initiated; no patients receiving booster inoculations have recurred.The E75 vaccine has clinical efficacy that is more prominent in certain patients. A phase 3 trial enrolling lymph node-positive patients with HER2 low-expressing tumors is warranted." @default.
• W2023685040 created "2016-06-24" @default.
• W2023685040 creator A5016000567 @default.
• W2023685040 creator A5029062544 @default.
• W2023685040 creator A5030342179 @default.
• W2023685040 creator A5034161793 @default.
• W2023685040 creator A5035073441 @default.
• W2023685040 creator A5044161354 @default.
• W2023685040 creator A5050537038 @default.
• W2023685040 creator A5060633487 @default.
• W2023685040 creator A5066190550 @default.
• W2023685040 creator A5073826514 @default.
• W2023685040 creator A5086555890 @default.
• W2023685040 date "2011-10-11" @default.
• W2023685040 modified "2023-09-27" @default.
• W2023685040 title "Clinical trial results of the HER-2/<i>neu</i>(E75) vaccine to prevent breast cancer recurrence in high-risk patients" @default.
• W2023685040 cites W1699177402 @default.
• W2023685040 cites W1961026612 @default.
• W2023685040 cites W1991228426 @default.
• W2023685040 cites W2023519138 @default.
• W2023685040 cites W2051289826 @default.
• W2023685040 cites W2067712862 @default.
• W2023685040 cites W2080595933 @default.
• W2023685040 cites W2086254893 @default.
• W2023685040 cites W2087231599 @default.
• W2023685040 cites W2101030466 @default.
• W2023685040 cites W2110250476 @default.
• W2023685040 cites W2146384083 @default.
• W2023685040 cites W2151447010 @default.
• W2023685040 cites W4232529261 @default.
• W2023685040 cites W4361867966 @default.
• W2023685040 doi "https://doi.org/10.1002/cncr.26574" @default.
• W2023685040 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3428069" @default.
• W2023685040 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21989902" @default.
• W2023685040 hasPublicationYear "2011" @default.
• W2023685040 type Work @default.
• W2023685040 sameAs 2023685040 @default.
• W2023685040 citedByCount "158" @default.
• W2023685040 countsByYear W20236850402012 @default.
• W2023685040 countsByYear W20236850402013 @default.
• W2023685040 countsByYear W20236850402014 @default.
• W2023685040 countsByYear W20236850402015 @default.
• W2023685040 countsByYear W20236850402016 @default.
• W2023685040 countsByYear W20236850402017 @default.
• W2023685040 countsByYear W20236850402018 @default.
• W2023685040 countsByYear W20236850402019 @default.
• W2023685040 countsByYear W20236850402020 @default.
• W2023685040 countsByYear W20236850402021 @default.
• W2023685040 countsByYear W20236850402022 @default.
• W2023685040 countsByYear W20236850402023 @default.
• W2023685040 crossrefType "journal-article" @default.
• W2023685040 hasAuthorship W2023685040A5016000567 @default.
• W2023685040 hasAuthorship W2023685040A5029062544 @default.
• W2023685040 hasAuthorship W2023685040A5030342179 @default.
• W2023685040 hasAuthorship W2023685040A5034161793 @default.
• W2023685040 hasAuthorship W2023685040A5035073441 @default.
• W2023685040 hasAuthorship W2023685040A5044161354 @default.
• W2023685040 hasAuthorship W2023685040A5050537038 @default.
• W2023685040 hasAuthorship W2023685040A5060633487 @default.
• W2023685040 hasAuthorship W2023685040A5066190550 @default.
• W2023685040 hasAuthorship W2023685040A5073826514 @default.
• W2023685040 hasAuthorship W2023685040A5086555890 @default.
• W2023685040 hasBestOaLocation W20236850402 @default.
• W2023685040 hasConcept C121608353 @default.
• W2023685040 hasConcept C126322002 @default.
• W2023685040 hasConcept C141071460 @default.
• W2023685040 hasConcept C143998085 @default.
• W2023685040 hasConcept C203014093 @default.
• W2023685040 hasConcept C22070199 @default.
• W2023685040 hasConcept C2776872082 @default.
• W2023685040 hasConcept C2777863537 @default.
• W2023685040 hasConcept C2780849966 @default.
• W2023685040 hasConcept C530470458 @default.
• W2023685040 hasConcept C535046627 @default.
• W2023685040 hasConcept C71924100 @default.
• W2023685040 hasConceptScore W2023685040C121608353 @default.
• W2023685040 hasConceptScore W2023685040C126322002 @default.
• W2023685040 hasConceptScore W2023685040C141071460 @default.
• W2023685040 hasConceptScore W2023685040C143998085 @default.
• W2023685040 hasConceptScore W2023685040C203014093 @default.
• W2023685040 hasConceptScore W2023685040C22070199 @default.
• W2023685040 hasConceptScore W2023685040C2776872082 @default.
• W2023685040 hasConceptScore W2023685040C2777863537 @default.
• W2023685040 hasConceptScore W2023685040C2780849966 @default.
• W2023685040 hasConceptScore W2023685040C530470458 @default.
• W2023685040 hasConceptScore W2023685040C535046627 @default.
• W2023685040 hasConceptScore W2023685040C71924100 @default.
• W2023685040 hasIssue "10" @default.
• W2023685040 hasLocation W20236850401 @default.
• W2023685040 hasLocation W20236850402 @default.
• W2023685040 hasLocation W20236850403 @default.
• W2023685040 hasLocation W20236850404 @default.
• W2023685040 hasOpenAccess W2023685040 @default.
• W2023685040 hasPrimaryLocation W20236850401 @default.
• W2023685040 hasRelatedWork W1997906202 @default.
• W2023685040 hasRelatedWork W2033202788 @default.
• W2023685040 hasRelatedWork W2066747782 @default.
• W2023685040 hasRelatedWork W2163676795 @default.

• next